Marshall Financial Group LLC Acquires 306 Shares of Amgen Inc. (NASDAQ:AMGN)

Marshall Financial Group LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 9.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,590 shares of the medical research company’s stock after acquiring an additional 306 shares during the period. Marshall Financial Group LLC’s holdings in Amgen were worth $1,021,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. BOK Financial Private Wealth Inc. bought a new stake in shares of Amgen during the fourth quarter worth about $29,000. United Community Bank bought a new stake in shares of Amgen during the fourth quarter worth about $29,000. Planned Solutions Inc. bought a new stake in shares of Amgen during the fourth quarter worth about $30,000. Delos Wealth Advisors LLC grew its holdings in shares of Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares during the last quarter. Finally, Hartford Financial Management Inc. grew its holdings in shares of Amgen by 56.9% during the fourth quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock worth $33,000 after purchasing an additional 41 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.69% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN traded down $1.39 during trading on Thursday, reaching $309.38. The company’s stock had a trading volume of 1,000,711 shares, compared to its average volume of 2,340,821. The firm has a market cap of $165.96 billion, a price-to-earnings ratio of 44.20, a price-to-earnings-growth ratio of 2.81 and a beta of 0.58. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The firm has a 50 day moving average of $303.81 and a 200-day moving average of $292.91. Amgen Inc. has a 12 month low of $218.44 and a 12 month high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The firm had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.98 EPS. Research analysts expect that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Morgan Stanley boosted their price target on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a report on Friday, May 3rd. Royal Bank of Canada upped their target price on Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a report on Friday, June 14th. StockNews.com upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and upped their target price for the company from $230.00 to $300.00 in a report on Friday, May 3rd. Finally, Mizuho upped their target price on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $307.35.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.